According to a recent LinkedIn post from Sequel Med Tech, the company is collaborating with Senseonics to offer an automated insulin delivery solution that combines the twiist system with the Eversense 365 continuous glucose monitor, with data integration powered by Tidepool. The post suggests this is the first AID system compatible with Eversense 365, a CGM sensor designed for up to one year of use.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn content emphasizes potential benefits for diabetes patients by reducing the frequency of sensor changes and device re-pairing while aiming to maintain CGM accuracy. For investors, this integration may signal a strategic effort by Sequel Med Tech to differentiate its AID platform, deepen its presence in long-term diabetes management, and potentially expand its addressable market in the U.S. T1D segment.
The post notes that twiist is intended for U.S. patients with type 1 diabetes ages 6 and older and is available by prescription only, while Eversense 365 is indicated for adults 18 and older. These usage parameters indicate an initial focus on regulated, prescription-based revenue streams in the U.S. market, with future financial impact likely tied to adoption rates, payer coverage, and competitive positioning in the AID and CGM landscape.